Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

For 13 years, Marks led the FDA's Center for Biologics Evaluation and Research, the department in charge of reviewing and approving vaccines, genetic medicines and cell therapies.Please watch the ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...

Dr. Peter Marks led the FDA’s Center for Biologics Evaluation and Research. He was perhaps the agency’s best-known official.

Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...

Peter Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines, will leave ...

(Reuters) -Shares of U.S. drugmakers fell before the bell on Monday after reports that the Food and Drug Administration's top ...

Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...

Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...